Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2022 2021 Net Earnings, after tax- as reported $5,149 $6,197 Pre-tax Adjustments Intangible Asset Amortization expense 1,108 1,215 IPR&D 610 - Restructuring related 72 104 Acquisition, integration and divestiture related ¹ - (538) (Gains)/losses on securities 411 35 Medical Device Regulation 2 60 46 Consumer Health separation costs 102 - Other (7) - Tax Adjustments Tax impact on special item adjustments 3 (393) (113) Consumer Health separation tax related costs 96 - Tax legislation and other tax related (79) (22) Adjusted Net Earnings, after tax $7,129 $6,924 Average shares outstanding (Diluted) 2,666.5 2,672.7 Adjusted net earnings per share (Diluted) $2.67 $2.59 Operational adjusted net earnings per share (Diluted) $2.75 Notes: 1 2 3 First Quarter Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2 Pharmaceutical brands outside of the U.S. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre- tax special items in arriving at adjusted earnings. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed by the end of 2023. -- 1 of 4 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical MedTech Total WW As Reported (1.5)% 6.3% 5.9% 5.0% U.S. (3.4)% 2.9% 5.6% 2.7% International 0.0% 10.3% 6.3% 7.2% WW Currency (2.3) (3.0) (2.6) (2.7) U.S. - - - - International (4.1) (6.4) (4.8) (5.4) WW Operational 0.8% 9.3% 8.5% 7.7% U.S. (3.4)% 2.9% 5.6% 2.7% International 4.1% 16.7% 11.1% 12.6% Skin Health / Beauty Dr. Ci Labo - Sedona 0.6 0.1 U.S. 0.0 0.0 International 1.1 0.2 All Other Acquisitions and Divestitures 0.2 0.0 0.1 0.1 U.S. 0.2 0.0 0.1 0.1 International 0.1 0.0 0.1 0.1 WW Adjusted Operational 1.6% 9.3% 8.6% 7.9% U.S. (3.2)% 2.9% 5.7% 2.8% International 5.3% 16.7% 11.2% 12.9% Adjusted Operational Sales Growth FIRST QUARTER 2022 ACTUAL vs. 2021 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum. -- 2 of 4 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Reported Income Before Tax by Segment $ 686 842 3,924 5,169 1,477 1,629 (123) (211) (102) - 5,862 7,429 % to Sales 19.1% 23.1% 30.5% 42.7% 21.2% 24.8% -0.5% -0.9% -0.4% 0.0% 25.0% 33.3% Intangible asset amortization expense 94 106 760 856 254 253 - - - - 1,108 1,215 In-process research and development - - 610 - - - - - - - 610 - Loss/(gain) on securities - (2) 394 37 17 - - - - - 411 35 Restructuring related 14 28 (14) 20 72 56 - - - - 72 104 Acquisition, integration and divestiture related - - - (570) - 32 - - - - - (538) Medical Device Regulation - - - - 60 46 - - - - 60 46 Consumer Health separation costs - - - - - - - - 102 - 102 - Other - - - - - - (7) - - - (7) - Adjusted Income Before Tax by Segment $ 794 974 5,674 5,512 1,880 2,016 (130) (211) - - 8,218 8,291 % to Sales 22.1% 26.8% 44.1% 45.5% 27.0% 30.6% -0.6% -0.9% 0.0% 0.0% 35.1% 37.1% 1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in their respective regions Q1 YTD - Income Before Tax by Segment Dollars in Millions Consumer Health Separation Costs Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total -- 3 of 4 -- First Quarter Acquistion, integration First Quarter April 3, 2022 GAAP Intangible asset amortization Litigation expense, net Restructuring related and divestiture related (1) Medical Device Regulation Other April 3, 2022 Non-GAAP Cost of products sold 7,598 $ (1,108) (16) (22) 6,452 Selling, marketing and admin expenses 5,938 (6) 5,932 Research and development expense 3,462 (32) 3,430 Other (Income) / Expense (102) - - 14 - (411) (102) 7 (594) In-process research and development 610 (610) - Restructuring 70 (70) - Provision for taxes on income 713 168 (53) 138 12 - 96 11 23 (96) 79 (2) 1,089 Net Earnings 5,149 940 53 472 60 - 315 49 79 96 (79) (5) 7,129 First Quarter Acquistion, integration First Quarter April 4, 2021 GAAP Intangible asset amortization Litigation expense, net Restructuring related and divestiture related (1) Medical Device Regulation Other April 4, 2021 Non-GAAP Cost of products sold 7,063 $ (1,215) (27) (17) 5,804 Selling, marketing and admin expenses 5,432 (5) 5,427 Research and development expense 3,178 (24) 3,154 Other (Income) / Expense (882) - - (24) 538 (35) - (403) Restructuring 53 (53) - Provision for taxes on income 1,232 177 - 20 (101) 8 9 - - 22 - 1,367 Net Earnings 6,197 1,038 - 84 (437) 27 37 - - (22) - 6,924 (1) 2021 primarily includes gains on the divestiture of 2 Pharmaceutical brands outside of the United States. Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Consumer Health separation tax related costs In-process research and development (Loss)/gain on securities Consumer Health separation costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development (Loss)/gain on securities Consumer Health separation costs Tax legislation and other tax related -- 4 of 4 --